Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 2980 Published: December 30, 2021 Report Code: GMDGDHC13205IDB

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

The Multiple Myeloma Drugs in Development market research report provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.

What are the targets of the Multiple Myeloma pipeline drugs market?

The targets of the Multiple Myeloma pipeline drugs market are Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, CD3, Cells Expressing B Lymphocyte Antigen CD19, ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Cells Expressing SLAM Family Member 7, Leukocyte Surface Antigen CD47, Cells Expressing Syndecan 1, Histone Deacetylase 6, and Programmed Cell Death Protein 1.

Multiple Myeloma pipeline drugs market, by targets

Multiple Myeloma pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Multiple Myeloma pipeline drugs market?

The mechanisms of action of the Multiple Myeloma pipeline drugs market are Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, CD3 Agonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 Inhibitor, Cytotoxic To Cells Expressing SLAM Family Member 7, Leukocyte Surface Antigen CD47 Inhibitor, Cytotoxic To Cells Expressing Syndecan 1, Histone Deacetylase 6 Inhibitor, and B Cell Lymphoma 2 Inhibitor.

Multiple Myeloma pipeline drugs market, by mechanisms of action

Multiple Myeloma pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Multiple Myeloma pipeline drugs market?

The routes of administration in the Multiple Myeloma pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intraperitoneal, intratumor, intradermal, intralesional, intravesical, and intravenous drip.

Multiple Myeloma pipeline drugs market, by routes of administration

Multiple Myeloma pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Multiple Myeloma pipeline drugs market?

The molecule types in the Multiple Myeloma pipeline drugs market are small molecule, gene-modified cell therapy, monoclonal antibody, cell therapy, monoclonal antibody conjugated, fusion protein, oncolytic virus, subunit vaccine, synthetic peptide, and gene therapy.

Multiple Myeloma pipeline drugs market, by molecule types

Multiple Myeloma pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Multiple Myeloma pipeline drugs market?

Some of the key companies in the Multiple Myeloma pipeline drugs market are Bristol-Myers Squibb Co, Novartis AG, Pfizer Inc, Johnson & Johnson, Sanofi, AbbVie Inc, Amgen Inc, Shanghai YaKe Biotechnology Co Ltd, AstraZeneca Plc, and Gilead Sciences Inc.

Multiple Myeloma pipeline drugs market, by key companies

Multiple Myeloma pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, CD3, Cells Expressing B Lymphocyte Antigen CD19, ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Cells Expressing SLAM Family Member 7, Leukocyte Surface Antigen CD47, Cells Expressing Syndecan 1, Histone Deacetylase 6, and Programmed Cell Death Protein 1
Mechanisms of Action Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, Cytotoxic to Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, CD3 Agonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 Inhibitor, Cytotoxic To Cells Expressing SLAM Family Member 7, Leukocyte Surface Antigen CD47 Inhibitor, Cytotoxic To Cells Expressing Syndecan 1, Histone Deacetylase 6 Inhibitor, and B Cell Lymphoma 2 Inhibitor
Routes of Administration Intravenous, Oral, Parenteral, Subcutaneous, Intraperitoneal, Intratumor, Intradermal, Intralesional, Intravesical, And Intravenous Drip
Molecule Types Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Cell Therapy, Monoclonal Antibody Conjugated, Fusion Protein, Oncolytic Virus, Subunit Vaccine, Synthetic Peptide, and Gene Therapy
Key Companies Bristol-Myers Squibb Co, Novartis AG, Pfizer Inc, Johnson & Johnson, Sanofi, AbbVie Inc, Amgen Inc, Shanghai YaKe Biotechnology Co Ltd, AstraZeneca Plc, and Gilead Sciences Inc

This report provides:

  • A snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease).
  • Reviews of pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Key players involved in Multiple Myeloma (Kahler Disease) therapeutics and enlists all their major and minor projects.
  • Assessment of Multiple Myeloma (Kahler Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease).
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Players

  • 4SC AG

    A. Menarini Industrie Farmaceutiche Riunite Srl

    Aadi Bioscience Inc

    Abbisko Therapeutics Co Ltd

    AbbVie Inc

    Abcuro Inc

    ABL Bio Inc

    Actinium Pharmaceuticals Inc

    Active Biotech AB

    Adicet Bio Inc

    Aeglea BioTherapeutics Inc

    Affimed GmbH

    AGC Biologics SpA

    Allife Medical Science and Technology Co Ltd

    Allogene Therapeutics Inc

    Alphamab Oncology

    Ambrx Biopharma Inc

    Amgen Inc

    Anaveon AG

    Antaimmu BioMed Co Ltd

    Antengene Corp Ltd

    Antion Biosciences SA

    APIM Therapeutics AS

    APO-T BV

    Arcellx Inc

    Arch Oncology Inc

    Arcus Biosciences Inc

    Ariz Precision Medicine Inc

    Arjuna Therapeutics

    Arovella Therapeutics Ltd

    Ascenta Therapeutics Inc

    Ascentage Pharma Group International

    Asclepius Technology Company Group Suzhou Co Ltd

    Aslan Pharmaceuticals Ltd

    AstraZeneca Plc

    Asylia Therapeutics Inc

    Auransa Inc

    Aurigene Discovery Technologies Ltd

    Autolus Therapeutics Plc

    Avalo Therapeutics Inc

    Ayala Pharmaceuticals Inc

    Bantam Pharmaceutical LLC

    Bayer AG

    BeiGene Ltd

    Beijing Immunochina Pharmaceuticals Co Ltd

    Beijing Menlo Biotechnology Co Ltd

    Beijing Sunbio Biotech Co Ltd

    Bellicum Pharmaceuticals Inc

    Betta Pharmaceuticals Co Ltd

    BeyondSpring Inc

    Biocad

    BioCurate Pty Ltd

    BioLineRx Ltd

    Biomea Fusion Inc

    Biosion Inc

    BioVec Pharma Inc

    BioVie Inc

    Bivictrix Therapeutics PLC

    bluebird bio Inc

    Boehringer Ingelheim International GmbH

    Bristol-Myers Squibb Co

    C4 Therapeutics Inc

    Calithera Biosciences Inc

    CanBas Co Ltd

    Cantex Pharmaceuticals Inc

    Carbiogene Therapeutics Co Ltd

    Caribou Biosciences Inc

    CARsgen Therapeutics Ltd

    Cartesian Therapeutics Inc

    CASI Pharmaceuticals Inc

    CDR-Life Inc

    Cell Source Inc

    CellCentric Ltd

    Cellectar Biosciences Inc

    Cellectis SA

    Celleron Therapeutics Ltd

    Cellestia Biotech AG

    Cello Therapeutics Inc

    Cellular Biomedicine Group Inc

    Celularity Inc

    Celyad Oncology SA

    Centrax International Inc

    Ceptur Therapeutics Inc

    Checkpoint Therapeutics Inc

    Cheetah Cell Therapeutics Co Ltd

    Chia Tai Tianqing Pharmaceutical Group Co Ltd

    Chimerix Inc

    China Immunotech (Beijing) Biotechnology Co Ltd

    Chinook Therapeutics Inc

    Chong Kun Dang Pharmaceutical Corp

    Chongqing Precision Biotech Co Ltd

    CiMaas BV

    Cleave Therapeutics Inc

    Compugen Ltd

    Convalife

    Corvus Pharmaceuticals Inc

    CRISPR Therapeutics AG

    CSPC Pharmaceutical Group Ltd

    CStone Pharmaceuticals Co Ltd

    Curocell Inc

    Cyclacel Pharmaceuticals Inc

    Cyteir Therapeutics Inc

    Cytovia Therapeutics Inc

    Daiichi Sankyo Co Ltd

    DeuteRx LLC

    DexTech Medical AB

    Diverse Biotech Inc

    Eli Lilly and Co

    Elpis Biopharmaceuticals Corp

    EpicentRx Inc

    EpimAb Biotherapeutics Inc

    Epizyme Inc

    Eternity Bioscience Inc

    eTheRNA Immunotherapies NV

    Eureka Therapeutics Inc

    EUSA Pharma (UK) Ltd

    ExCellThera Inc

    Exelixis Inc

    F. Hoffmann-La Roche Ltd

    Fate Therapeutics Inc

    Fera Pharmaceuticals LLC

    Fortis Therapeutics Inc

    Fusion Pharmaceuticals Inc

    Gadeta BV

    Galileo Research srl

    Gamida Cell Ltd

    GEMoaB Monoclonals GmbH

    GemoPharm

    Genenta Science srl

    Genentech USA Inc

    Genmab AS

    Geron Corp

    Gilead Sciences Inc

    GlaxoSmithKline Plc

    Gliknik Inc

    GlycoMimetics Inc

    Glycostem Therapeutics BV

    GlyTR Therapeutics Inc

    GP Pharm SA

    Gracell Biotechnologies Inc

    GT Biopharma Inc

    Guangdong Zhongsheng Pharmaceutical Co Ltd

    Guangzhou Bio-gene Technology Co Ltd

    HaemaLogix Pty Ltd

    Hangzhou DAC Biotech Co Ltd

    Hangzhou Sumgen Biotech Co Ltd

    Harbin Gloria Pharmaceuticals Co Ltd

    Harbour BioMed (Guangzhou) Co Ltd

    Harpoon Therapeutics Inc

    Hebei Senlang Biotechnology Co Ltd

    Heidelberg Pharma AG

    Helix BioPharma Corp

    Helocyte Biosciences Inc

    Hengenix Biotech Inc

    Hinova Pharmaceuticals Co Ltd

    HitGen Inc

    Holy Stone Healthcare Co Ltd

    HRAIN Biotechnology Co Ltd

    Hummingbird Bioscience Pte Ltd

    Hunan Siweikang Therapeutics Ltd

    HuniLife Biotechnology Inc

    Hutchison MediPharma Ltd

    I-Mab

    iCell Gene Therapeutics LLC

    Ichnos Sciences Inc

    IDAC Theranostics Inc

    IDP Discovery Pharma SL

    IGM Biosciences Inc

    Immix BioPharma Inc

    ImmuneCyte Inc

    ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

    ImmuneTarget Inc

    Immunicum AB

    ImmunityBio Inc

    Immunotech Biopharm Ltd

    Immunwork Inc

    Incyte Corp

    Indapta Therapeutics Inc

    Inflection Biosciences Ltd

    Inmune Bio Inc

    InnoCare Pharma Ltd

    Innovative Cellular Therapeutics Co Ltd

    Intra-Immusg Pvt Ltd

    Inventiva SA

    IO Biotech Inc

    Io Therapeutics Inc

    Ionis Pharmaceuticals Inc

    Ionova Life Science Co Ltd

    Istesso Ltd

    iTeos Therapeutics Inc

    Iterion Therapeutics Inc

    Jiangsu Carephar Pharmaceutical Co Ltd

    Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd

    Jiangsu Hansoh Pharmaceutical Group Co Ltd

    Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd

    Jiangxi Shanxing Biotechnology Co Ltd

    JN Biosciences LLC

    Johnson & Johnson

    JSK Therapeutics Inc

    Jubilant Therapeutics Inc

    Juventas Cell Therapy Ltd

    JW Pharmaceutical Corp

    K36 Therapeutics Inc

    Kangpu Biopharmaceuticals Ltd

    Karyopharm Therapeutics Inc

    KeyMed Biosciences Inc

    Kiadis Pharma NV

    KisoJi Biotechnology Inc

    Klyss Biotech Inc

    Kodikaz Therapeutic Solutions Inc

    Komipharm International Co Ltd

    Kronos Bio Inc

    KYAN Therapeutics Inc

    Kymab Ltd

    Laekna Therapeutics Shanghai Co Ltd

    LAVA Therapeutics NV

    Leadiant Biosciences Inc

    Legend Biotech Corp

    Les Laboratoires Servier SAS

    Leukogene Therapeutics Inc

    Ligand Pharmaceuticals Inc

    LintonPharm Co Ltd

    Lokon Pharma AB

    Loxo Oncology Inc

    Luminus Biosciences Inc

    Luye Pharma Group Ltd

    Mablink Bioscience

    Machavert Pharmaceuticals LLC

    Marker Therapeutics Inc

    Max Biopharma Inc

    MediGene AG

    MedPacto Inc

    Merck & Co Inc

    Millennium Pharmaceuticals Inc

    Miltenyi Biotec BV & Co KG

    MimiVax LLC

    MiNK Therapeutics Inc

    Modulation Therapeutics Inc

    Molecular Partners AG

    Molecular Templates Inc

    Morphogenesis Inc

    MorphoSys AG

    Multitude therapeutics Inc

    Mustang Bio Inc

    Mycovia Pharmaceuticals Inc

    Nanexa AB

    Nanjing Aimeifei Biomedical Technology Co Ltd

    Nanjing Bioheng Biotech Co Ltd

    Nanjing Iaso Biotherapeutics Co Ltd

    Nektar Therapeutics

    Neoleukin Therapeutics Inc

    Neomics Pharmaceuticals LLC

    Neonc Technologies Inc

    Nerviano Medical Sciences SRL

    Newave Pharmaceutical Inc

    NewBay Medical Technology Co Ltd

    NexImmune Inc

    Northlake International LLC

    Novartis AG

    Oncodesign SA

    OncoFusion Therapeutics Inc

    Oncolytics Biotech Inc

    OncoMyx Therapeutics Inc

    Onconova Therapeutics Inc

    OncoPep Inc

    Oncopeptides AB

    OncoTartis Inc

    OncoTherapy Science Inc

    One World Cannabis Ltd

    ONK Therapeutics Ltd

    Ono Pharmaceutical Co Ltd

    Onward Therapeutics SA

    Orgenesis Inc

    ORIC Pharmaceuticals Inc

    Origincell Technology Group Co Ltd

    Otsuka Pharmaceutical Co Ltd

    Paras Biopharmaceuticals Finland Oy

    PentixaPharm GmbH

    PersonGen Anke Cellular Therapeutics Co Ltd

    PersonGen Biomedicine Suzhou Co Ltd

    Pfizer Inc

    Pharma Mar SA

    Phi Pharma SA

    Phosplatin Therapeutics LLC

    PI Therapeutics Ltd

    Pimera Inc

    Pinotbio Inc

    Poseida Therapeutics Inc

    Precision Biosciences Inc

    Pregene ShenZhen Biotechnology Co Ltd

    Prelude Therapeutics Inc

    Prescient Therapeutics Ltd

    Protheragen Inc

    Qilu Pharmaceutical Co Ltd

    Quadriga BioSciences Inc

    Qwixel Therapeutics LLC

    Rapa Therapeutics LLC

    RAPT Therapeutics Inc

    Raqia Therapeutics Inc

    Regeneron Pharmaceuticals Inc

    RESTEM

    SA Science Inc

    Sana Biotechnology Inc

    Sanofi

    Seagen Inc

    SELLAS Life Sciences Group Inc

    Senhwa Biosciences Inc

    Shandong New Time Pharmaceutical Co Ltd

    Shanghai Biomed-Union Biotechnology Co Ltd

    Shanghai Bioray Laboratory Inc

    Shanghai GeneChem Co Ltd

    Shanghai Junshi Bioscience Co Ltd

    Shanghai Keqi Pharmaceutical Technology Co Ltd

    Shanghai Novamab Biopharmaceuticals Co Ltd

    Shanghai Theorion Pharmaceutical Co Ltd

    Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

    Shanghai YaKe Biotechnology Co Ltd

    Shanghai Yingli Pharmaceutical Co Ltd

    Shenogen Pharma Group Ltd

    Shenzhen Chipscreen Biosciences Co Ltd

    Shenzhen Neptunus Institute of Pharmaceutical Technology Co Ltd

    Shenzhen Targetrx Inc

    Shuttle Pharmaceuticals Inc

    Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

    Sichuan Kelun Pharmaceutical Co Ltd

    SignalRx Pharmaceuticals Inc

    SignPath Pharma Inc

    Sorrento Therapeutics Inc

    SpecificiT Pharma Inc

    Sphaera Pharma Pte Ltd

    SpringWorks Therapeutics Inc

    Starton Therapeutics Inc

    Sumitomo Dainippon Pharma Oncology

  • Inc

    Sunnycell Therapeutics Ltd

    Sunomix Therapeutics

    Surface Oncology Inc

    Sutro Biopharma Inc

    Suzhou Maximum Bio-tech Co Ltd

    Synactix Pharmaceuticals Inc

    SynDevRx Inc

    T-Cure Bioscience Inc

    T-CURX GmbH

    Taiho Oncology Inc

    TaiRx Inc

    Takeda Pharmaceutical Co Ltd

    Targazyme Inc

    Telix Pharmaceuticals Ltd

    Tianweiyuan and Biomedicine Shanghai Co Ltd

    TiCARos Co Ltd

    Tiziana Life Sciences Plc

    Tmunity Therapeutics Inc

    Transgene Biotek Ltd

    Triterpenoid Therapeutics Inc

    Triumvira Immunologics Inc

    TSD Life Sciences

    TTY Biopharm Co Ltd

    Ube Industries Ltd

    Up Therapeutics Inc

    VaxcellBio Inc

    Vaxil Bio Therapeutics Ltd

    Verastem Inc

    Vichem Chemie Research Ltd

    Vincerx Pharma Inc

    Visterra Inc

    Vycellix Inc

    Vyriad Inc

    Wellington Zhaotai Therapies Ltd

    Wigen Biomedicine Technology (Shanghai) Co Ltd

    WindMIL Therapeutics Inc

    Wugen Inc

    Wuhan Bio-Raid Biotechnology Co Ltd

    Wuhan YZY Biopharma Co Ltd

    XBiotech Inc

    XEME BioPharma Inc

    Xencor Inc

    Xi’An Yufan Biotechnology Co Ltd

    Xiangxue Life Sciences

    XNK Therapeutics AB

    Zhengda Tianqing Pharmaceutical Group Co Ltd

    Zovis Pharmaceuticals

    Zymergen Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Multiple Myeloma (Kahler Disease) – Overview

Multiple Myeloma (Kahler Disease) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Multiple Myeloma (Kahler Disease) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Multiple Myeloma (Kahler Disease) – Companies Involved in Therapeutics Development

Multiple Myeloma (Kahler Disease) – Drug Profiles

Multiple Myeloma (Kahler Disease) – Dormant Projects

Multiple Myeloma (Kahler Disease) – Discontinued Products

Multiple Myeloma (Kahler Disease) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodol’ogy

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Multiple Myeloma (Kahler Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Multiple Myeloma (Kahler Disease) – Dormant Projects, 2021

Multiple Myeloma (Kahler Disease) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Multiple Myeloma (Kahler Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.